BELLICUM PHARMACEUTICALS INC's ticker is and the CUSIP is 079481404. A total of 31 filers reported holding BELLICUM PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $0 | -100.0% | 1 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | – | 1 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 105,144 | $781,000 | 0.07% |
| Alyeska Investment Group, L.P. | 200,000 | $1,486,000 | 0.02% |
| Caption Management, LLC | 90,000 | $669,000 | 0.02% |
| Sio Capital Management, LLC | 7,751 | $58,000 | 0.02% |
| SHUFRO ROSE & CO LLC | 12,941 | $96,000 | 0.01% |
| Baker Brothers Advisors | 249,123 | $1,851,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 29,180 | $217,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 7,030 | $52,000 | 0.00% |
| Tekla Capital Management LLC | 6,000 | $45,000 | 0.00% |
| Renaissance Technologies | 185,071 | $1,375,000 | 0.00% |